The pathophysiology of primary pulmonary hypertension

British Journal of Cardiology

Volumn 9, Issue 5, 2002, Pages 265-266+268

  Mikhail, Ghada W ^a   Gibbs, J Simon R ^a   Yacoub, Magdi H ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Pathophysiology; Primary pulmonary hypertension; WHO classification

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; AMINOREX; ANOREXIGENIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CALCIUM ION; CHLORPHENTERMINE; CYTOKINE; DEXFENFLURAMINE; ELASTASE; ENDOTHELIN 1; ESTER DERIVATIVE; FATTY ACID; FENFLURAMINE; FIBRINOPEPTIDE A; MATRIX METALLOPROTEINASE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR; POTASSIUM CHANNEL; POTASSIUM ION; PROSTACYCLIN RECEPTOR; PROSTACYCLIN SYNTHASE; SEROTONIN; SEROTONIN TRANSPORTER; TENASCIN; THROMBOMODULIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

AUTOIMMUNITY; DEATH; DISEASE CLASSIFICATION; DISEASE COURSE; FUNCTIONAL ASSESSMENT; GENETIC SUSCEPTIBILITY; HEART RIGHT VENTRICLE FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFLAMMATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SCIENCE; WORLD HEALTH ORGANIZATION;

EID: 0036572830     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Primary pulmonary hypertension. A national prospective study
2. Primary pulmonary hypertension
3. Primary pulmonary hypertension in the elderly
4. Primary pulmonary hypertension: Case series from France
5. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998
6. Primary pulmonary hypertension between inflammation and cancer
7. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
8. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension
9. Multiple phenotypically distinct smooth muscle cell populations exist in the adult and developing pulmonary arterial media in vivo
10. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular matrix-bound basic fibroblast growth factor
11. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation
12. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension
13. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension
14. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32
15. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32
16. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension
17. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor membrane of the TGF-β family
18. BMPR-2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension
19. Aminorex and pulmonary hypertension. A review
20. Aminorex to Fen/Phen. An epidemic foretold
21. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group
22. Hormonal responses to fenfluramine in depressed and control subjects
23. Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle cells and cause pulmonary vasoconstriction
24. Action of fenfluramine on voltage gated K+ channels in human pulmonary artery smooth-muscle cells
25. Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension
26. An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain
27. Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study
28. Factors associated with pathogenicity of oils related to the toxic oil syndrome epidemic in Spain
29. The acute pathology of fatty acid anilides and linoleic diester of 3-phenylamino-1,2-propanediol in mice; Possible implication as aetiologic agents for the toxic oil syndrome
30. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
31. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
32. Role of vasoactive mediators in primary and secondary pulmonary hypertension
33. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
34. Reduced expression of prostacyclin receptor protein on remodelled vessels in pulmonary hypertension
35. Prostacyclin synthase expression is decreased in lungs with severe pulmonary hypertension
36. Increased plasma serotonin in primary pulmonary hypertension
37. Anorectic drugs and pulmonary hypertension from the bedside to the bench
38. Pulmonary hypertension in patients using oral contraceptives. A report of six cases
39. Oral contraceptives and progressive pulmonary vascular disease
40. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone
41. Physiological roles and properties of potassium channels in arterial smooth muscle
42. Voltage-gated K+ currents regulate resting membrane potential and Ca 2+ in pulmonary arterial myocytes
43. Attenuated K+ channel gene transcription in primary pulmonary hypertension
44. Primary pulmonary hypertension. A pathologic study of the lung vessels in 156 clinically diagnosed cases
45. Primary pulmonary hypertension
46. Pulmonary hypertension in systemic sclerosis
47. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)
48. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis
49. Pulmonary hypertension in dermatomyositis
50. Pulmonary hypertension. Report of a case in association with rheumatoid arthritis
51. Pulmonary hypertension in a patient with rheumatoid arthritis
52. Pulmonary hypertension in the lupus clinic: Experience with twenty four patients.
53. Hypothyroidism and primary pulmonary hypertension: An autoimmune pathogenetic link?
54. Antinuclear antibodies in primary pulmonary hypertension
55. Pulmonary hypertension in patients with HIV infection
56. Tat-protein of HIV enhances inflammatory cell binding and PDGF levels in CMV infected endothelial cells
57. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients
58. Primary pulmonary hypertension in association with pulmonary hypertension infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy
59. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension
60. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection
61. Vascular remodelling in primary pulmonary hypertension
62. Vascular endothelial growth factor (VEGF) expression in normal and remodeled pulmonary arteries in severe pulmonary hypertension
63. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension
64. Chemokine macrophage inflammatory protein-1α mRNA expression in lung biopsy specimens of primary pulmonary hypertension
65. 5-Lipoxygenase and 5-Lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension